When standard antidepressants don’t work, patients often turn to more intensive therapies like electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine-based treatments. These powerful interventions can help many people with treatment-resistant depression, but not everyone responds equally. Why? A growing body of research suggests the answer might be hidden in our genes.
Why Genes May Matter in Mental Health Treatments
While each person’s experience with depression is different, scientists are beginning to find patterns in how our genetic makeup may affect the way we respond to certain treatments. The field is still in its early stages, but researchers are hoping to find clues that can guide treatment decisions more precisely in the future.
So far, studies have focused on genes like COMT and BDNF, which are involved in how brain chemicals like dopamine and serotonin work. These early investigations tried to connect specific gene variants with how well patients responded to ECT or ketamine. Unfortunately, many of these findings haven’t been consistently replicated. That means we can’t yet use them reliably in clinical practice.
A Call for Larger Studies
One of the main challenges in this field is the lack of large-scale studies. Most genetic studies on treatment response in depression involve small groups of participants, which limits their ability to detect significant patterns. Only one genome-wide association study (GWAS) so far has included more than 1,000 people. Without larger sample sizes, it’s hard to tell which genetic signals truly matter.
To address this, researchers from around the world have joined forces in a project called Gen-ECT-ic, a 50-site global collaboration aiming to collect genetic data from thousands of patients who have received ECT and other intensive treatments. The hope is to discover specific DNA markers that can help predict which treatments will work best for which patients.
Why This Matters for the Future of Psychiatry
Understanding the genetics of treatment response in depression could change everything about how we treat mental illness. Imagine being able to test your genes before starting treatment, allowing your doctor to recommend the therapy most likely to work for you. This kind of personalized psychiatry could reduce the trial-and-error process that many patients go through, leading to faster relief and fewer side effects.
It could also save time, resources, and lives. For patients with severe, treatment-resistant depression, every delay in finding the right therapy can be devastating. A more targeted approach could offer real hope for those who haven’t responded to traditional options.
The Role of Genetics in ECT, TMS, and Ketamine Response
Each treatment—whether it’s ECT, TMS, or ketamine—likely involves different biological pathways, which means genetic predictors of response may vary between them. As more research is published, we may begin to identify which patients will benefit most from one treatment over another based on their genetic profile.
While we’re not there yet, the science is moving in the right direction. With large-scale initiatives like Gen-ECT-ic and increasing global collaboration, personalized psychiatry could soon become a reality.
Discover more with Interventional Psychiatry Network.
Citations
- Genetics of response to ECT, TMS, ketamine, and esketamine — now confirmed via PubMed: Franklin C E, Altinay M, Bailey K, et al. Genetics of Response to ECT, TMS, Ketamine and Esketamine. Am J Med Genet B Neuropsychiatr Genet. Published online June 17, 2025. PMID: 40525674; DOI: 10.1002/ajmg.b.33038 med.stanford.edu+3pubmed.ncbi.nlm.nih.gov+3pemf-devices.com+3
- Amare, A. T., Schubert, K. O., Hou, L., et al. (2021). Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Molecular Psychiatry, 26(6), 2457–2470. https://doi.org/10.1038/s41380-020-0689-5